A Multicenter, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects ≥ 1 Month < 16 Years of Age With Epilepsy
Phase of Trial: Phase II
Latest Information Update: 23 Dec 2018
At a glance
- Drugs Brivaracetam (Primary)
- Indications Epilepsy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors UCB Biopharma
- 08 Jun 2018 Status changed from not yet recruiting to recruiting.
- 04 Jun 2018 Planned End Date changed from 1 Feb 2020 to 1 Jul 2020.
- 04 Jun 2018 Planned primary completion date changed from 1 Feb 2020 to 1 Jul 2020.